| Literature DB >> 29403837 |
Jamshed Haneef1, Mohammad Shaharyar1, Asif Husain1, Mohd Rashid1, Ravinesh Mishra1, Shama Parveen1, Niyaz Ahmed1, Manoj Pal2, Deepak Kumar3.
Abstract
Liquid chromatography tandem mass chromatography (LC-MS/MS) is an important hyphenated technique for quantitative analysis of drugs in biological fluids. Because of high sensitivity and selectivity, LC-MS/MS has been used for pharmacokinetic studies, metabolites identification in the plasma and urine. This manuscript gives comprehensive analytical review, focusing on chromatographic separation approaches (column packing materials, column length and mobile phase) as well as different acquisition modes (SIM, MRM) for quantitative analysis of glucocorticoids and stimulants. This review is not meant to be exhaustive but rather to provide a general overview for detection and confirmation of target drugs using LC-MS/MS and thus useful in the doping analysis, toxicological studies as well as in pharmaceutical analysis.Entities:
Keywords: Biological fluid; Glucocorticoids; Hyphenated techniques; Ionization techniques; LC–MS/MS; Stimulants
Year: 2013 PMID: 29403837 PMCID: PMC5760999 DOI: 10.1016/j.jpha.2013.03.005
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
General nucleus of corticoids and different substitutions of different glucocorticoids drugs..
| Steroid name | Δ1, 2 | R6 | R9 | R11 | R16 | R17 | R21 |
|---|---|---|---|---|---|---|---|
| Hydrocortisone | Saturated | 3H | 3H | 3–OH | 3H | 3–OH | 3–OH |
| Cortisone | Saturated | 3H | 3H | åO | 3H | 3–OH | 3–OH |
| Corticosterone | Saturated | 3H | 3H | 3–OH | 3H | 3H | 3–OH |
| Fludrocortisone | Saturated | 3H | 3F | 3–OH | 3H | 3–OH | 3–OH |
| Prednisolone | Double bond | 3H | 3H | 3–OH | 3H | 3–OH | 3–OH |
| Prednisone | Double bond | 3H | 3H | åO | 3H | 3–OH | 3–OH |
| Methylprednisolone | Double bond | 3–CH3 | 3H | 3–OH | 3H | 3–OH | 3–OH |
| Prednisolone acetate | Double bond | 3H | 3H | 3–OH | 3H | 3–OH | 3–OCOCH3 |
| Dexamethasone | Double bond | 3H | 3F | 3–OH | 3–OH | 3–OH | |
| Betamethasone | Double bond | 3H | 3F | 3–OH | 3–OH | 3–OH | |
| Beclomethasone | Double bond | 3H | 3Cl | 3–OH | 3–OH | 3–OH | |
| Triamcinolone | Double bond | 3H | 3F | 3–OH | 3–OH | 3–OH | 3–OH |
| Triamcinolone acetonide | Double bond | 3H | 3F | 3–OH | 3–OH | ||
Selected confirmatory methods for detecting glucocorticoids in biological fluids.
| Analyte | Matrix | Pretreatment | Column; mobile phase | Detection mode | LOD | Ref. |
|---|---|---|---|---|---|---|
| 9 Synthetic corticosteroids | Urine | LLE with Extrelut-NT3 columns | Inertsil ODS-3 C18 column (150 mm×3 mm, 3 μm); 1 mM ammonium acetate pH 6.8/ACN (60:40, v/v) at 0.4 mL/min | ESI negative SIM mode | 1 ng/mL | |
| 20 Corticosteroids | Urine | Enzymatic hydrolysis C-8 SCX SPE Cartridge | Supelcosil LC-8-DBcolumn (2.1 mm×3.3 cm, 3 μm); 5 mM acetic acid/10 mM ammonium acetate (pH 3.8)/methanol, at 0.2 mL/min | ESI positive MRM | 0.1–10 ng/mL | |
| Methylprednisolone methylprednisolone acetate | Plasma | Protein precipitation | Sinergy Max RP C-12 column (2.0 mm×150 mm, 4 μm); 0.01% formic acid in water/ACN (50:50, v/v) at 0.2 mL/min | ESI positive MRM | 6–300 ng/mL | |
| 17 Synthetic glucocorticoids | Urine | Enzymatic hydrolysis followed by LLE | BEH C18 column(2.1 mm×50 mm, 1.7 μm); 0.1% formic acid in ACN/0.1% formic acid in water, at 0.35 mL/min | TOF-MS with ESI positive | 0.1–3.3 μg/L | |
| Methylprednisolone | Methylprednisolone Plasma | LLE | Pursuit C-18 column (2.0 mm×150 mm, 5 μm); ACN/0.5% formic acid aq. solution (85:15, v/v) at 0.2 mL/min | ESI positive SRM | 20–2000 ng/mL | |
| 5 Corticosteroids: dexamethasone, flumethasone, fluorometholone, beclomethasone, triamcinolone acetonide | Urine | Enzymatic hydrolysis Oasis-HLB SPE column | Alltima C-18 column (2.1 mm × 150 mm, 5 µm); ACN/water(40:60, v/v) at 0.3 mL/min | APCI positive SRM mode | 2–3 ng/mL | |
| Cortisol, cortisone, prednisolone, prednisone | Plasma | Protein precipitation | Zorbax-SB phenyl, HT rapid resolution column (2.1 mm×100 mm, 1.8 μm); ACN/H2O/ formic acid(32:68:0.1, v/v) at 0.140 mL/min | APCI positive MRM mode | 0.5–2 ng/mL | |
| Prednisone, prednisolone, dexamethasone, cortisol | Human serum | SPE | Symmetry C-18 column (2.1 mm×30 mm, 3.5 μm); methanol/5 mM acetate buffer pH 3.25 at 400 μL/min | ESI negative MRM mode | 0.2–0.5 ng/mL | |
| Cortisol, dexamethasone, prednisone, prednisolone, methylprednisolone | Plasma | SPE Oasis HLB Cartridge | Symmetry C-18 column (2.1 mm×30 mm, 3.5 μm); 5 mM ammonium acetate buffer pH 3.5 and methanol (95:5, v/v)/methanol and 5 mM ammonium acetate buffer pH 3.5 (95:5, v/v), at 400 μL/min | ESI negative MRM mode | 3–7 ng/mL | |
| 21 Synthetic corticosteroids | Urine | Enzymatic hydrolysis followed by LLE | RP DB-8 column (4.6 mm×75 mm, 3 μm); 1% acetic acid/ methanol, at 1 mL/min | APCI positive full scan mode | 5 ng/mL | |
| Cortisol, cortisone, prednisolone, dexamethasone, 11-deoxycortisol | Plasma, urine saliva, plasma-ultra filtrate | SPE Oasis HLB 1 cm3 Cartridge | Acquity UPLC BEH C-18 column (2.1 mm×50 mm, 1.7 μm); | ESI positive MRM | 0.6–5 nM | |
| 16 Glucocorticoids | Urine | Enzymatic hydrolysis followed by LLE | Halo C-18 column(2.1 mm×150 mm, 2.7 μm and 2.1 mm×100 mm, 2.7 μm); water with 0.1% formic acid/ACN with 0.1% formic acid at 400 μL/min | ESI positive MRM | 5–15 ng/mL | |
| 15 Synthetic glucocorticoids | Urine | Enzymatic hydrolysis followed by LLE | Zorbax C-18 column (2.1 mm×50 mm, 1.8 μm); 0.1% acetic acid/ACN with 0.1% acetic acid at 0.3 mL/min | ESI positive MRM | 1–30 ng/mL | |
| 14 Glucocorticoids | Urine | Enzymatic hydrolysis followed by LLE | Inertsil ODS-3 C18 column(50 mm×4.6 mm, 3 μm); 1% formic acid/ACN, at 700 μL/min | ESI positive MRM | 1–5 ng/mL |
Ref.—References.
Selected confirmatory methods for detecting stimulants in biological fluids.
| Analyte | Matrix | Pretreatment | Column; Mobile phase | Detection mode | LOD | Ref. |
|---|---|---|---|---|---|---|
| 9 Stimulants including strychnine, methylphenidate, amiphenazole, famprofazone, tuaminoheptan | Urine | Enzymatic hydrolysis followed by LLE | Halo C-18 column (2.1 mm ×150 mm, 2.7 μm and 2.1 mm×100 mm, 2.7 μm); water with 0.1% formic acid/ACN with 0.1% formic acid at 400 μL/min | ESI positive MRM | 70–300 ng/mL | |
| Mesocarb, modafinil, formoterol | Urine | Enzymatic hydrolysis followed by LLE | Zorbax C-18 column (2.1 mm×50 mm,1.8 μm); 0.1% acetic acid/ACN with 0.1% acetic acid at 0.3 mL/min | ESI positive MRM | 100–200 ng/mL | |
| Methylphenidate, mesocarb | Urine | Enzymatic hydrolysis followed by LLE | Inertsil ODS-3 C18 column(50 mm×4.6 mm, 3 μm); 1% formic acid/ACN, at 700 μL/min | ESI positive MRM | 5 ng/mL | |
| 49 Stimulants | Urine | Enzymatic hydrolysis SPE cartridge | Phenomex Luna C-18 column( 2 mm ×100 mm, 3 μm); 5 mM ammonium acetate with 0.1% formic acid/ ACN, at 0.3 mL/min | ESI positive | 0.025 μg/mL | |
| 27 Amphetamine and amphetamine like drugs | Urine | LLE | Omnispher C-18 column (3.0 mm×50 mm, 3 μm); 0.1% formic acid/methanol, at 0.4 mL/min | APCI positive full scan MS | 1–25 ng/mL | |
| 7 Amphetamine derivatives: AP, MA, MDA, MDMA,MDEA, DMA, DMANO | Urine | Oasis HLB SPE | Capcell C-18 MG-II column (2.0 mm×150 mm, 5 μm); 5 mM ammonium formate pH 4.0/ACN, at 230 μL/min | ESI positive MRM | 1.95 ng/mL | |
| Mesocarb | Urine | Enzymatic hydrolysis followed by LLE | Thermo-Hyper Gold C-18 (2.1 mm×50 mm, 3 μm ); 15 mM ammonium formate containing 1% formic acid/ACN at 200 μL/min | SRM positive | 5 ng/mL | |
| AP, MA, MDA, MDMA, MDEA, PMA, ephedrine | Urine | LLE | Acquity UPLC HSS C-18 column(2.1 mm×100 mm, 1.8 μm ); 5 mM ammonium formate buffer containing 0.05% formic acid/methanol, at 0.3 mL/min | ESI positive MRM | 0.5–2.5 ng/mL |
AP: amphetamine, MA: methamphetamine, MDA: 3,4-methylenedioxy-N-amphetamine, DMA: N, N-dimethylamphetamine, PMA: p-hydroxymethamphetamine, MDMA: 3,4-methylenedioxy-N-methamphetamine, MDEA: 3,4-methylenedioxy-N-ethylamphetamine, DMANO: N, N-dimethyl amphetamine-N-oxide, SPE: solid phase extraction, LLE: liquid–liquid extraction, ACN: acetonitrile, Ref: references.
Empirical formula, exact masses, MS fragmentation data, Log P and λ of selected glucocorticoids and stimulants.
| Drug name | Empirical formula | Exact mass | [M+H]+ | m/z of major fragments reported | Log | Ref. | |
|---|---|---|---|---|---|---|---|
| Amphetamine | C9H13N | 135.10480 | 136.2 | 119.2, 91.2 | 1.8 | 257, 263 | |
| MDA | C10H13NO2 | 179.09463 | 180.2 | 163, 134.9, 105 | 1.64 | 233, 285 | |
| MDMA | C11H15 NO2 | 193.11028 | 194.1 | 163.2, 105.1 | 2.15 | 234, 285 | |
| Beclomethasone | C22H29ClO5 | 408.17035 | 409.18 | 391, 373, 337 | 2.03 | 239 | |
| Betamethasone | C22H29FO5 | 392.19990 | 393 | 337, 355, 241, 147 | 1.94 | 240 | |
| Budesonide | C25H34O6 | 430.23554 | 431 | 413, 341, 323, 173 | 2.18 | 248 | |
| Dexamethasone | C22H29FO5 | 392.19990 | 393 | 373, 355, 337, 237, 147 | 1.83 | 240 | |
| Fludrocortisone | C21H29FO5 | 380.19990 | 381 | 343, 239 | 1.67 | 240 | |
| Flumethasone | C22H28F2O5 | 410.19047 | 411 | 371, 335, 253, 121 | 1.9 | 238 | |
| Fluocortolone | C22H29FO4 | 376.20499 | 377 | 321, 303 | 2.1 | 242 | |
| Methylphenidate | C14H19NO2 | 233.14158 | 234 | 174, 129, 84, 56 | 0.20 | 264 | |
| Methylprednisolone | C22H30O5 | 374.20932 | 375 | 357, 339, 161 | 1.82 | 240 | |
| Prednisolone | C21H28O5 | 360.19367 | 361 | 343, 325, 147, 307 | 1.62 | 240 | |
| Prednisone | C21H26O5 | 358.17802 | 359 | 341, 323, 267, 147, 34 | 1.46 | 240 | |
| Strychnine | C21H22N2O2 | 334.16813 | 335 | 264, 184, 156 | 1.9 | 255 | |
| Triamcinolone | C21H27FO6 | 394.17917 | 395 | 357, 321, 225 | 1.16 | 238 | |
| Triamcinolone | C24H31FO6 | 434.21047 | 435 | 415, 397, 213 | 1.2 | 238 | |
| Acetonide |
Values obtained from online SRC Phys Prop Database, Ref.—References.
Characteristics fragment ions of glucocorticoids obtained in ESI negative mode LC–MS/MS.
| Analyte | |
|---|---|
| Cortisone | 329.2 |
| Dexamethasone | 361.2 |
| Hydrocortisone | 331.2 |
| Flumethasone | 379.2 |
| Flunisolide | 375.2 |
| Methylpednisolone | 343.2 |
| Prednisolone | 329.2 |
| Prednisone | 327.2 |
| Triamcinolone | 345.2 |
| Triamcinolone acetonide | 413.2 |
Indicate base peak.
Fig. 1Proposed mass fragmentation pathway of dexamethasone drug. 1—Molecular ion peak at M+=393. 2—Base ion peak at m/z=373. 3—Daughter ion peak at m/z=355.
Fig. 2Proposed mass fragmentation pathway of prednisolone drug. 1—Molecular ion peak at M+=361. 2—Base ion peak at m/z=343. 3—Daughter ion peak at m/z=307.
Fig. 3Proposed mass fragmentation pathway of prednisone drug. 1—Molecular ion peak at M+=359. 2—Base ion peak at m/z=341. 3—Daughter ion peak at m/z=171.
Fig. 4Proposed mass fragmentation pathway of strychnine drug. 1—Molecular ion peak at M+=335. 2—Base ion peak at m/z=264. 3—Daughter ion peak at m/z=156.